福泰制药
VRTX
499.74
-9.01
-1.77%
福泰制药
US · VRTX
#155 按市值排名
上市于 1970
499.74
-9.01
-1.77%
实时 - 追踪5344个代码 - 心跳于163秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了3家。
- 机构持股总比例下降了0.1个百分点。
机构持股
- 机构持股比例
- 97.01% -0.11pp
- 机构数量
- 2,097 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund86.61%
Public Company3.21%
Hedge Fund1.90%
Government Pension Fund1.88%
Private Company1.38%
Sovereign Wealth Fund1.26%
Insurance Company0.30%
Individual/Insider0.20%
Family Office/Trust0.18%
Other3.07%
主要股东 截至 2026-06-30
Capital Research
20.05% · 50.81M 股
BlackRock
9.51% · 24.11M 股
Vanguard Capital Management, LLC
7.10% · 18.01M 股
State Street Global Advisors
4.68% · 11.87M 股
Invesco Capital Management LLC
2.93% · 7.43M 股
Other
55.72%
Geode Capital Management, LLC
2.37% · 6.02M 股
J.P. Morgan Asset Management, Inc.
2.12% · 5.38M 股
Vanguard Portfolio Management, LLC
1.92% · 4.88M 股
Loomis, Sayles & Company L.P.
1.55% · 3.92M 股
UBS Asset Management
1.50% · 3.80M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 25次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Amit Sachdev | Executive VP & Chief Patient Officer | 0.03% |
| Stuart Arbuckle | Chief Operating Officer | 0.03% |
| Ourania Tatsis | Executive VP and Chief Regulatory & Quality Officer | 0.02% |
| Reshma Kewalramani | Chief Executive Officer | 0.02% |
| Bruce Sachs | Lead Independent Director | 0.02% |
| Jeffrey Leiden | Executive Chairperson | 0.01% |
| David Altshuler | Executive VP of Global Research & Chief Scientific Officer | 0.01% |
| Charles Wagner | Chief Financial Officer | 0.01% |
| Joy Liu | Corporate Secretary | 0.01% |
| Edward Atkinson | EVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-07 | Jasper van Grunsven | Executive VP & Chief Pain & New Product Planning Officer | Other Acquisition | +8,682 | -- |
| 2026-08-27 | Kristen Ambrose | Chief Accounting Officer | Other Acquisition | +5,000 | -- |
| 2026-08-26 | Bruce Sachs | Lead Independent Director | Other Disposition | -6,000 | -- |
| 2026-07-20 | Amit Sachdev | Executive VP & Chief Patient Officer | Other Acquisition | +8,251 | -- |
| 2026-07-20 | Ourania Tatsis | Executive VP and Chief Regulatory & Quality Officer | Other Acquisition | +8,251 | -- |
| 2026-07-14 | Bruce Sachs | Lead Independent Director | Other Derivative Acquisition | +99 | -- |
| 2026-07-14 | Alan Garber | Independent Director | Other Derivative Acquisition | +31 | -- |
| 2026-07-01 | Ourania Tatsis | Executive VP and Chief Regulatory & Quality Officer | Automatic Disposition | -1,500 | $524.99 |
| 2026-07-01 | Duncan McKechnie | Senior VP & Head of North America Commercial | Automatic Disposition | -1,541 | $519.00 |
| 2026-06-30 | Joy Liu | Corporate Secretary | Automatic Disposition | -828 | $502.71 |
| 2026-06-25 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -596 | $482.50 |
| 2026-06-17 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,020 | $462.17 |
| 2026-06-14 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -4,062 | $450.00 |
| 2026-06-04 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,745 | $450.00 |
| 2026-05-31 | Joy Liu | Corporate Secretary | Automatic Disposition | -828 | $439.91 |
| 2026-05-28 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,974 | $450.00 |
| 2026-05-14 | Mark Bunnage | Senior VP & Head of Research | Automatic Disposition | -33 | $453.45 |
| 2026-05-14 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,354 | $453.45 |
| 2026-05-11 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -6,988 | $450.00 |
| 2026-05-05 | Jonathan Biller | Chief Legal Officer | Intent to Sell (Form 144) | -5,193 | $424.25 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:19 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
福泰制药 讨论区 0 条评论